NRC 2694A

Drug Profile

NRC 2694A

Alternative Names: NRC-2694; NRC-2694-A

Latest Information Update: 12 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Natco Pharma
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Solid tumours

Most Recent Events

  • 01 Feb 2016 Phase I development is ongoing in India
  • 13 Jan 2014 Phase-I clinical trials in Solid tumours and breast cancer (late-stage disease) in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top